Squarepoint Ops LLC acquired a new stake in Compass Therapeutics, Inc. (NASDAQ:CMPX – Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 24,072 shares of the company’s stock, valued at approximately $35,000. A number of other large investors have also recently added to or reduced their stakes in the business. Rhumbline Advisers grew its stake in Compass Therapeutics by 3.1% in the 4th quarter. Rhumbline Advisers now owns 129,116 shares of the company’s stock valued at $187,000 after acquiring an additional 3,822 shares during the last quarter. Invesco Ltd. grew its stake in Compass Therapeutics by 11.3% in the 4th quarter. Invesco Ltd. now owns 39,483 shares of the company’s stock valued at $57,000 after acquiring an additional 4,018 shares during the last quarter. Bank of New York Mellon Corp grew its stake in Compass Therapeutics by 2.6% in the 4th quarter. Bank of New York Mellon Corp now owns 237,975 shares of the company’s stock valued at $345,000 after acquiring an additional 6,041 shares during the last quarter. ProShare Advisors LLC grew its stake in Compass Therapeutics by 49.0% in the 4th quarter. ProShare Advisors LLC now owns 28,722 shares of the company’s stock valued at $42,000 after acquiring an additional 9,451 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its stake in Compass Therapeutics by 31.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 46,942 shares of the company’s stock valued at $69,000 after acquiring an additional 11,326 shares during the last quarter. 68.43% of the stock is owned by institutional investors and hedge funds. Analyst Upgrades and Downgrades CMPX has been the topic of several analyst reports. Guggenheim decreased their price target on shares of Compass Therapeutics from $12.00 to $10.00 and set a “buy” rating on the stock in a research note on Friday, May 9th. Leerink Partners raised shares of Compass Therapeutics from a “market perform” rating to an “outperform” rating and raised their price target for the stock from $4.00 to $6.00 in a research note on Wednesday, April 2nd. Wedbush reaffirmed an “outperform” rating and set a $8.00 price target on shares of Compass Therapeutics in a research note on Tuesday, April 1st. D. Boral Capital reaffirmed a “buy” rating and set a $32.00 price target on shares of Compass Therapeutics in a research note on Monday, April 28th. Finally, Leerink Partnrs raised shares of Compass Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, April 1st. Eight analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $13.13. View Our Latest Stock Analysis on CMPX Insiders Place Their Bets In related news, insider Jonathan Anderman acquired 20,000 shares of Compass Therapeutics stock in a transaction that occurred on Monday, April 7th. The stock was acquired at an average price of $1.54 per share, with a total value of $30,800.00. Following the completion of the acquisition, the insider now directly owns 21,000 shares of the company’s stock, valued at $32,340. This trade represents a 2,000.00% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Carl L. Gordon sold 3,571,428 shares of the business’s stock in a transaction dated Wednesday, April 9th. The stock was sold at an average price of $1.59, for a total transaction of $5,678,570.52. The disclosure for this sale can be found here. 29.80% of the stock is currently owned by corporate insiders. Compass Therapeutics Stock Performance CMPX opened at $2.51 on Wednesday. The company’s 50 day simple moving average is $1.95 and its 200 day simple moving average is $2.17. Compass Therapeutics, Inc. has a 1 year low of $0.77 and a 1 year high of $4.08. The stock has a market capitalization of $347.09 million, a PE ratio of -6.78 and a beta of 1.41. Compass Therapeutics (NASDAQ:CMPX – Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.12) EPS for the quarter, meeting the consensus estimate of ($0.12). As a group, sell-side analysts expect that Compass Therapeutics, Inc. will post -0.36 earnings per share for the current fiscal year. Compass Therapeutics Company Profile (Free Report) Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.

BOSTON, May 28, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that the Company will participate in a fireside chat at the Jefferies Global Healthcare Conference taking place June 3-5, 2025. Fireside Chat Details Date: Thursday, June 5, 2025Time: 11:05 – 11:35 AM ETWebcast Link: https://wsw.com/webcast/jeff319/cmpx/1867328 Virtual/Replay availability: The fireside chat will be archived for 90 days on Compass' Events page.

Compass Therapeutics' tovecimig shows promise in biliary tract cancer with a 17.1% response rate, but further survival data is crucial for potential approval. CMPX's cash runway extends into early 2027, providing financial stability to reach key milestones and possibly raise funds from a stronger position. Other pipeline candidates, CTX-471 and CTX-8371, have upcoming trials and readouts in 2025, adding potential value to CMPX's portfolio.

Tovecimig (DLL4 x VEGF-A bispecific antibody) met the primary endpoint in the ongoing randomized Phase 2/3 Study in patients with biliary tract cancer (BTC). Achieved a 17.1% overall response rate (ORR), including one complete response, compared to a 5.3% ORR for paclitaxel alone, in patients with BTC treated in the second-line setting.

BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that the Company will participate in the following investor events during the month of May. Details are as follows: The Citizens Life Sciences Conference Location: New York, NY Date: Thursday, May 8, 2025 Time: 1:30 PM ET Webcast Link: https://wsw.com/webcast/jmp65/cmpx/1692592 H.C.

CTX-471 monotherapy demonstrated efficacy in multiple murine models, including models highly resistant to immune checkpoint inhibitors. Combining CTX-471 with tovecimig (CTX-009) markedly increased anti-tumor efficacy in these models.

Summary ⚈ Market conditions in May create opportunities for penny stock investors.⚈ Compass Therapeutics and Blade Air Mobility are highlighted for strong growth prospects.

BOSTON, April 21, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, announced the first patient has been dosed in an Investigator Sponsored Trial (IST) to evaluate tovecimig (CTX-009, a DLL4 x VEGF-A bispecific antibody) for the first time in the front-line setting for patients with biliary tract cancer (BTC). The IST is being conducted at The University of Texas MD Anderson Cancer Center.

BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will present at the Stifel 2025 Virtual Targeted Oncology Forum taking place April 8-9, 2025.

Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel achieved a 17.1% overall response rate (ORR), including one complete response, compared to 5.3% ORR for paclitaxel alone, in patients with biliary tract cancer (BTC) treated in the second-line setting. The difference in ORR between the two treatment arms, the primary endpoint of the study, was statistically significant (p=0.031), and all responses have been confirmed by blinded independent central radiology review.